瑞财经 王敏 4月30日，据港交所官网，安序源科技Axbio International Limited（以下简称"安序源"）在 港交所递交招股书，拟在香港主板挂牌上市，中金公司和浦银国际担任联席保荐人。 招股书显示，安序源成立于2016年，作为全球集成电路生物科技的领导者，致力开发新一代电化学检测 平台以实现生命科学工具及诊断产业的革新。公司融合了集成电路、生物科技及人工智能技术，致力于 为生命科学研究及临床应用打造先进的基础平台。 截至2025年4月21日，安序源的产品管线包括一款微数组芯片分析仪、两款EL-NGS基因测序仪，以及 多种配套检测试剂盒。 | 【得囊]的[得囊]數目 | : | [编纂](視乎[编纂]行使與否而定) | | --- | --- | --- | | [篇纂]數目 | : | [搞纂](可予重新分配) | | [編纂]數目 | : | [编纂](可予重新分配及視乎[编纂]行使與 | | | | 合而定) | | 最高[編纂] : | | 每股[編纂][編纂]港元,另加1.0%經紀佣金、 | | | | 0.00015% 會 財局交易 徵 費 、0.0027% 證 監 會 | | ...

公 司 报 告 计算机 2025年05月05日 华大九天(301269.SZ) 一季度利润表现良好，国内EDA领先地位持续稳固 推荐 ( 维持) 股价:119.19元 行情走势图 证券分析师 | 闫磊 | 投资咨询资格编号 | | --- | --- | | | S1060517070006 | | | YANLEI511@pingan.com.cn | | 黄韦涵 | 投资咨询资格编号 | S1060523070003 HUANGWEIHAN235@pingan.com.cn 事项： 公司公告2024年年报和2025年一季报。2024年，公司实现营业收入12.22亿 元，同比增长20.98%；实现归母净利润1.09亿元，同比减少45.46%。2025年 一季度，公司实现营业收入2.34亿元，同比增长9.77%；实现归母净利润0.10 亿元，同比增长26.72%。公司发布利润分配预案：以542,941,768为基数，向 全体股东每10股派发现金红利1.50元（含税），送红股0股（含税），以资本 公积金向全体股东每10股转增0股。 平安观点： 券 研究助理 | 王佳一 | 一般证券从业资格编号 | | --- ...

目前，清华大学、北京大学、中国人民大学等39所高校均已发布2025年强基计划招生简章。中青报·中 青网记者梳理发现，今年不少高校在招生专业及计划部分不仅延续了王牌专业的招生趋势，而且新增培 养方向大多围绕服务国家战略性新兴领域，进一步储备国家急需高层次人才。 此外，在招生对象及报名条件上，部分高校在今年的招生简章中淡化对竞赛成绩的要求，甚至取消 了"高中阶段须在数学、物理、化学、生物学、信息学任一学科奥林匹克竞赛中获得全国决赛二等奖及 以上奖项"的第二类报名条件，以高考成绩为重要参考标准。在破格入围方式上，单科成绩"破格入 围"的方式仍然存在，但部分学校进一步细化了破格入围的规则。在培养方式上，试点高校普遍采取导 师制、小班化、个性化等方式进行培养，为学生配备了一流的师资条件、科研资源。 新增培养方向对接国家战略前沿领域 据悉，今年是强基计划实施的第六年。目前已有39所试点高校，在数学、物理、化学、生物、力学、历 史、哲学、古文字学、基础医学等基础学科以及生物育种等国家重大战略领域相关专业招生。 2025年，多所高校强基计划新增培养方向与学校优势学科强相关。北京理工大学发布的2025年强基计划 招生简章中显示 ...

最高人民检察院日前发布的《知识产权检察工作白皮书(2024)》显示，检察机关依法加强关键核心技术 刑事保护，聚焦新一代信息技术、人工智能、高端装备、生物医药、集成电路等关键核心技术，突出加 强对高新技术、新兴产业、未来产业等领域知识产权的司法保护，服务因地制宜发展新质生产力。据统 计，2024年，全国检察机关共受理审查起诉侵犯商业秘密犯罪163件385人，案件数同比上升12.4%。最 高检指导上海、浙江、广东等地办理了一批涉人工智能、芯片制造、动力电池等在创新密集型领域有重 大影响的案件和新类型案件。(新华社) ...

据 IPO早知道消息， Axbio International Limited – B （以下简称 " 安序源科技 "）于2025年4月30日正式向港交所递交招股说明书，拟主板挂牌上 市，中金公司和浦银国际担任联席保荐人。 成立于 2016年的安序源科技 融合了集成电路 (IC)、生物科技(BT) 和 人工智能 （ AI ） 技术，致力于为生命科学研究 和 临床应用打造先进的基础平 台。 其中，安序源科技 的开创性解决方案包括分子诊断产品 、用 于多组学分析的新一代电化学长读长测序平台 (EL-NGS) 与 生物芯片，以及基于 自 身 技术 与 平台基础的延伸服务。 | 産品 | 主要應用 | | | | | 開發階段 | | | 當前階段 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 市場／監管機構 | 類別 | | | | | | 預期／實際 | | | | | | 設計 | 設計驗證 | 型檢(1) | 臨床試驗 | 註冊批准 | 完成日期 | | 設備 | | | | | | | | | | | 微陣列分析儀 ...

公司研究 单位租金稳步上涨，分红派息保持稳定 ——上海临港（600848.SH）2024 年报及 2025 年一季报点评 要点 事件：公司发布 2024 年年报及 2025 年一季报 2024 年，公司实现营业总收入 111.03 亿元，（调整后）同比增长 57.2%；实 现归母净利润 10.97 亿元，（调整后）同比增长 3.1%。 2025 年一季度，公司实现营业总收入 15.81 亿元，（调整后）同比下降 17.1%； 实现归母净利润 1.72 亿元，（调整后）同比下降 16.5%。 点评：经营业绩略超预期，单位租金稳步上涨，分红派息保持稳定 2025 年 4 月 30 日 经营业绩略超预期：2024 年公司实现营业收入 111.03 亿元（我们预测为 82 亿 元），实现归母净利润 10.97 亿元（我们预测为 9.5 亿元），略超预期。原因主 要为 2024 年园区销售业务实现营收 74.77 亿元（同比增长 100.97%），实现结 转面积 35.41 万平方米（同比增长 159.2%）。 单位租金稳步上涨：2024 年公司出租房地产的建筑面积约为 269.9 万平方米（同 比下降 13.9%）， ...

Core Company Overview - Axbio International Limited, founded in 2016, is a leader in integrated circuit biotechnology, focusing on developing next-generation electrochemical detection platforms for life sciences and diagnostics [1] - The company integrates integrated circuits, biotechnology, and artificial intelligence to create advanced foundational platforms for life science research and clinical applications [1] Key Technologies and Products - The company specializes in four key areas: integrated circuit chips, synthetic biology and chemical engineering, electrochemistry and microfluidics, and artificial intelligence, with AI being central to its innovation strategy [1] - AxiLona EL-100 is a molecular diagnostic product capable of multi-target detection, offering high sensitivity and rapid testing cycles, filling a market gap between PCR instruments and gene sequencers [3] - The AxiLona AXP-100 gene sequencer is the world's first EL-NGS platform, achieving optimal balance in accuracy, read length, cost, and speed, suitable for both clinical applications and research needs [4] Product Pipeline and Development - The product pipeline includes a microarray chip analyzer, two EL-NGS gene sequencers, and various supporting test kits [2] - The company plans to expand the clinical application of AxiLona EL-100 by adding protein detection capabilities to capture significant market opportunities [3] - AxiLona AXP-1000 is in development, featuring a high-throughput sequencing chip with ten million nanopore channels, expected to have ten times the throughput of AxiLona AXP-100 [4] Research and Development Strategy - The company has established four R&D centers in Silicon Valley, Shenzhen, Tianjin, and Wuxi, equipped with advanced facilities to support innovative research [5] - The core R&D team has nearly 100 authorized patents globally, with several more pending, showcasing a strong commitment to innovation [5] - The team comprises experts with backgrounds from prestigious institutions and organizations, ensuring a high level of expertise in semiconductor, biotechnology, and artificial intelligence [5]

Core Points - The Beijing Expert Association held its sixth first member representative conference, electing a new council with notable academicians in leadership roles [1] - The association, established in 1990, serves as a vital platform for connecting and serving experts and talents in Beijing, now boasting over a thousand members [1] - The association has optimized its member structure, enhancing representation and coverage across various fields [1] Subgroup 1: Leadership and Structure - The new leadership includes Chinese Academy of Engineering Academician Zhan Qimin as the chairman and several other prominent academicians as vice-chairmen [1][2] - The association has set up eight sub-committees led by 70 academicians, focusing on areas such as basic research, electronic information, and high-end manufacturing [2] Subgroup 2: Talent Development - Approximately one-third of the members are around 40 years old, representing young leading talents engaged in significant scientific projects and technological challenges [3] - Nearly 60% of the members come from fields like integrated circuits, artificial intelligence, and healthcare, indicating a strong focus on high-tech sectors [3] Subgroup 3: Future Initiatives - The association plans to create a core intellectual property (IP) of high-level experts in the capital, focusing on national strategic implementation and addressing critical technological challenges [4] - It aims to enhance political guidance for talents and strengthen communication with members through various educational and research activities [4] - The association will establish a talent identification mechanism and a platform for technology transfer, aiming to discover and cultivate high-potential young talents in the capital [4]

Investment Rating - The investment rating for the company is "Buy" and is maintained [2] Core Views - The company reported a revenue of 547 million yuan in 2024, representing a year-on-year increase of 14.50%. However, the net profit attributable to shareholders decreased by 37.68% to 80.27 million yuan [5][6] - In Q1 2025, the company achieved a revenue of 66.48 million yuan, a significant year-on-year growth of 51.43%, but reported a net loss attributable to shareholders of 13.71 million yuan [5][6] - The company is focusing on enhancing its EDA product matrix, particularly in DFT and DFM tools, which are crucial for improving chip yield and manufacturing efficiency [7][8] Company Overview - The latest closing price of the company's stock is 48.50 yuan, with a total market capitalization of 9.7 billion yuan [4] - The company has a total share capital of 200 million shares, with 108 million shares in circulation [4] - The company has a low debt-to-asset ratio of 7.6% and a high price-to-earnings ratio of 121.25 [4] Financial Performance - The company’s revenue is projected to grow to 705 million yuan in 2025, 903 million yuan in 2026, and 1.201 billion yuan in 2027, with corresponding net profits of 112.75 million yuan, 180.74 million yuan, and 268.95 million yuan respectively [10][12] - The company’s gross margin improved from 60.30% in 2023 to 61.90% in 2024, indicating better cost management and product mix [6] - The R&D expenses increased by 33.49% in 2024, reflecting the company's commitment to innovation and product development [6] Investment Recommendations - The current stock price corresponds to a price-to-earnings ratio of 86 times for 2025, 54 times for 2026, and 36 times for 2027, supporting the "Buy" rating [10][12]

Investment Rating - The report maintains a "Buy" rating for the company [2][10] Core Views - The company reported a revenue of 547 million yuan in 2024, representing a year-on-year increase of 14.50%. However, the net profit attributable to shareholders decreased by 37.68% to 80.27 million yuan [5][6] - In Q1 2025, the company achieved a revenue of 66.48 million yuan, a significant year-on-year growth of 51.43%, but reported a net loss of 13.71 million yuan [5][6] - The company is focusing on enhancing its EDA product matrix, particularly in DFT and DFM tools, which are crucial for improving chip yield and manufacturing efficiency [7][8] Summary by Sections Company Overview - The latest closing price is 48.50 yuan, with a total market capitalization of 9.7 billion yuan and a total share capital of 200 million shares [4] Financial Performance - In 2024, the company’s revenue was 547 million yuan, with software development and licensing contributing 159 million yuan, a 70.33% increase year-on-year. The gross margin improved from 60.30% in 2023 to 61.90% in 2024 [6] - The company’s R&D expenses increased by 33.49% due to a rise in the number of R&D personnel from 416 to 522 [6] Investment Highlights - The company is a leading supplier of EDA software and wafer-level electrical testing equipment, focusing on improving chip yield and providing comprehensive solutions throughout the product lifecycle [7] - The acquisition of a 43% stake in Shanghai Yirui Chip Electronics Technology Co., Ltd. marks the company's expansion from manufacturing EDA to design EDA [9] Earnings Forecast - The company is projected to achieve revenues of 705 million yuan, 903 million yuan, and 1.201 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding net profits of 112.75 million yuan, 180.74 million yuan, and 268.95 million yuan [10][12]